Search
Results: 8
The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro.
Rafia S Al-Lamki, Nicholas J Hudson, John R Bradley, Anne Y Warren, Tim Eisen, Sarah J Welsh, Antony CP Riddick, Fiach C O'Mahony, Arran Turnbull, Thomas Powles, Scotrrcc Collaborative, Antonio Reverter, David J Harrison, Grant D Stewart
Apr 03, 2020
Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we...
Sunitinib for Metastatic Renal Cell Carcinoma
Michael Moran, Dana Nickens, Katherine Adcock, Meg Bennetts, Arial Desscan, Natalie Charnley, Kate Fife
Jul 11, 2020
BACKGROUND: Randomized controlled trials (RCTs) have stringent inclusion criteria and may not fully represent patients seen in everyday clinical practice. Real-world data (RWD) can provide supportive evidence for the...
Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
Sarah J Welsh, Nicola Thompson, Anne Warren, Andrew N Priest, Tristan Barrett, Stephan Ursprung, Ferdia A Gallagher, Fulvio Zaccagna, Grant D Stewart, Kate M Fife, Athena Matakidou, Andrea J Machin, Wendi Qian, Victoria Ingleson, Jean Mullin, Antony CP Riddick, James N Armitage, Stephen Connolly, Timothy GQ Eisen
Nov 03, 2021
Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma.
Stephan Ursprung, Andrew N Priest, Fulvio Zaccagna, Wendi Qian, Andrea Machin, Grant D Stewart, Anne Y Warren, Timothy Eisen, Sarah J Welsh, Ferdia A Gallagher, Tristan Barrett
Jan 06, 2022
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma
Tobias Klatte, Kate Fife, Sarah J Welsh, Manavi Sachdeva, James N Armitage, Tevita 'Aho, Antony C Riddick, Athena Matakidou, Tim Eisen, Grant D Stewart
Feb 23, 2018
PURPOSE: To test the hypothesis that cytoreductive nephrectomy (CN) improves overall survival (OS) of patients with synchronous metastatic renal cell carcinoma (mRCC), who subsequently receive targeted therapies (TT). METHODS...
Nephrectomy Pazopanib Prognosis Sunitinib survival Aged Anilides Antibodies Monoclonal Antineoplastic Agents Carcinoma Renal Cell Cohort Studies Combined Modality Therapy Cytoreduction Surgical Procedures Female Humans Indazoles Indoles Kaplan-Meier Estimate Kidney Neoplasms Liver Neoplasms Lung Neoplasms Male Middle Aged Molecular Targeted Therapy Neoplasm Metastasis Nephrectomy Nivolumab Probability Prognosis Proportional Hazards Models Pyridines Pyrimidines Pyrroles Retrospective Studies Sex Factors Sulfonamides Sunitinib Survival Rate Thrombocytosis
The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
Rafia S. Al-Lamki, Nicholas J. Hudson, John R. Bradley, Anne Y. Warren, Tim Eisen, Sarah J. Welsh, Antony C. P. Riddick, Fiach C. O’Mahony, Arran Turnbull, Thomas Powles, SCOTRRCC Collaborative SCOTRRCC Collaborative, Antonio Reverter, David J. Harrison, Grant D. Stewart
Apr 08, 2020
Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we...
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.
Meta HM Diekstra, Jesse J Swen, Loes FM van der Zanden, Sita H Vermeulen, Epie Boven, Ron HJ Mathijssen, Koya Fukunaga, Taisei Mushiroda, Fumiya Hongo, Egbert Oosterwijk, Anne Cambon-Thomsen, Daniel Castellano, Achim Fritsch, Jesus Garcia Donas, Cristina Rodriguez-Antona, Rob Ruijtenbeek, Marius T Radu, Tim Eisen, Kerstin Junker, Max Roessler, Ulrich Jaehde, Tsuneharu Miki, Stefan Böhringer, Michiaki Kubo, Lambertus ALM Kiemeney, Henk-Jan Guchelaar
Jul 24, 2022
Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim is to provide...
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Robert Hawkins, Kate Fife, Michael Hurst, Meng Wang, Niroshini Naicker, Sarah Nolasco, Tim Eisen, Athena Matakidou, Jason Gordon
Oct 02, 2020
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have demonstrated favourable outcomes in randomised controlled trials, however real-world evidence is limited. Thus, this...
Molecular Targeted Therapy renal cancer Survival Analysis Adolescent Adult Aged Antineoplastic Agents Axitinib Carcinoma Renal Cell Everolimus Female Follow-Up Studies Humans Indazoles Kaplan-Meier Estimate Kidney Neoplasms Longitudinal Studies Male Middle Aged Molecular Targeted Therapy Practice Patterns Physicians' Prognosis Protein Kinase Inhibitors Pyrimidines Retrospective Studies Sulfonamides Sunitinib Treatment Outcome United Kingdom Young Adult